Uncategorized

Nektar’s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs

Published

4 hours ago

on

Nektar Therapeutics prices $325 million public offering: The Bay Area biotech is selling about 3.5 million shares of stock at $92 per share. The proceeds will fund “general corporate purposes,” including …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version